Journal of Virology, December 2003, p. 12996-13004, Vol. 77, No. 24
0022-538X/03/$08.00+0 DOI: 10.1128/JVI.77.24.12996-13004.2003
Copyright © 2003, American
Society for
Microbiology. All Rights Reserved.
Intra- and Intermolecular Disulfide Bonds of the GP2b Glycoprotein of Equine Arteritis Virus: Relevance for Virus Assembly and Infectivity
Roeland Wieringa,
Antoine A. F. de Vries,
Sabine M. Post,
and Peter J. M. Rottier*
Department
of Infectious Diseases and Immunology, Virology Division, Faculty of
Veterinary Medicine, and Institute of Biomembranes, Utrecht
University, 3584 CL Utrecht, The Netherlands
Received 23 April 2003/
Accepted 14 September 2003
 |
ABSTRACT
|
|---|
Equine
arteritis virus (EAV) is an enveloped, positive-strand RNA virus
belonging to the family Arteriviridae of the order
Nidovirales. EAV virions contain six different envelope
proteins. The glycoprotein GP5 (previously named
GL) and the unglycosylated membrane protein M are the major
envelope proteins, while the glycoproteins GP2b (previously
named GS), GP3, and GP4 are minor
structural proteins. The unglycosylated small hydrophobic envelope
protein E is present in virus particles in intermediate molar amounts
compared to the other transmembrane proteins. The GP5 and M
proteins are both essential for particle assembly. They occur as
covalently linked heterodimers that constitute the basic protein matrix
of the envelope. The GP2b, GP3, and
GP4 proteins occur as a heterotrimeric complex in which
disulfide bonds play an important role. The function of this complex
has not been established yet, but the available data suggest it to be
involved in the viral entry process. Here we investigated the role of
the four cysteine residues of the mature GP2b protein in the
assembly of the GP2b/GP3/GP4 complex.
Open reading frames encoding cysteine-to-serine mutants of the
GP2b protein were expressed independently or from a
full-length infectious EAV cDNA clone. The results of these experiments
support a model in which the cysteine residue at position 102 of
GP2b forms an intermolecular cystine bridge with one of the
cysteines of the GP4 protein, while the cysteine residues at
positions 48 and 137 of GP2b are linked by an intrachain
disulfide bond. In this model, another cysteine residue in the
GP4 protein is responsible for the covalent association of
GP3 with the disulfide-linked GP2b/GP4
heterodimer. In addition, our data highlight the importance of the
correct association of the minor EAV envelope glycoproteins for their
efficient incorporation into viral particles and for virus
infectivity.
 |
INTRODUCTION
|
|---|
Equine arteritis virus (EAV) is an enveloped, positive-strand
RNA virus which belongs to the genus Arterivirus. Other
members of this single genus in the family Arteriviridae are
Lactate dehydrogenase-elevating virus (LDV), Porcine
reproductive and respiratory syndrome virus (PRRSV), and
Simian hemorrhagic fever virus. On the basis of conserved
amino acid sequence motifs in their polymerase (poly)proteins and
similarities in their genome organization and gene expression strategy,
the Arteriviridae have been grouped together with the
Coronaviridae and the recently established family
Roniviridae in the order Nidovirales
(2,
3,
4).
The genome of
EAV contains nine functional open reading frames (ORFs). ORF1a and -1b
occupy the 5' three-fourths of the genome and code for proteins
involved in viral replication and transcription
(6,
25,
29,
30,
32). The remaining
one-fourth of the viral genome contains seven relatively small ORFs
(ORF2a, -2b, and -3 through -7), which are expressed from a
3'-coterminal nested set of six leader-containing subgenomic
mRNAs (RNA2 through -7)
(8,
26) and code for the
known viral structural proteins
(9,
24,
34). In each of these
subgenomic mRNAs, only the functional ORF positioned immediately
downstream of the leader sequence is translated, with the exception of
RNA2, which directs the synthesis of both the ORF2a and -2b products
(24).
EAV virions
have a diameter of 40 to 60 nm and are thought to possess an
icosahedral core that is surrounded by a lipid-containing envelope with
small surface protrusions
(16,
19). The viral core
consists of the EAV genome, an unsegmented RNA molecule of 12.7 kb with
a 5' cap and a 3' poly(A) tail which is encapsidated by
the 14-kDa phosphorylated nucleocapsid (N) protein
(5,
17,
35). The N protein is
encoded by ORF7
(9).
In the envelope
of EAV, six different proteins have been identified so far. The two
major envelope proteins are the GP5 glycoprotein (previously
named GL), which varies in size from 30 to 42 kDa due to the
addition of variable numbers of lactosamine repeats to its single
N-linked glycan, and the 16-kDa nonglycosylated membrane protein (M).
These proteins occur in virions in equimolar amounts and are encoded by
ORF5 and -6, respectively
(9). The third most
abundant protein in the viral membrane is the envelope protein (E) of
10 kDa. This protein lacks N-linked oligosaccharide side chains and is
encoded by ORF2a (24).
The remaining envelope proteins are the 25-kDa GP2b
glycoprotein (previously named GS), the heterogeneously
N-glycosylated GP3 glycoprotein of 37 or 42 kDa, and the
28-kDa GP4 glycoprotein. These three polypeptides constitute
the minor envelope proteins of EAV and are present in virus particles
in equimolar amounts. They are encoded by ORF2b, -3, and -4,
respectively (11,
34).
The M and
GP5 proteins appear in EAV particles as disulfide-linked
heterodimers (10). The
GP2b, GP3, and GP4 proteins are
present in virions as heterotrimeric complexes (see below for more
details). The higher order structure of the E protein in virus
particles is unknown, but there are indications that it is
noncovalently associated with the
GP2b/GP3/GP4 trimers (R. Wieringa et
al., unpublished data). While M and GP5 are essential for
EAV assembly (Wieringa et al., unpublished data), they do not determine
the cell tropism of the virus. Exchange of the ectodomain of the EAV
GP5 protein with that of LDV or PRRSV in the context of a
full-length EAV cDNA clone did not alter the host cell range of the
virus (12). Likewise,
PRRSV mutants in which the ectodomain of the M protein was replaced by
that of other arteriviruses retained their original cell tropism
(31). Since noninfectious
viral particles are produced in the absence of the GP2b,
GP3, or GP4 protein
(22,
24; Wieringa et al.,
unpublished data), it is likely that the complex of minor envelope
glycoproteins mediates (initial) virus attachment to the host cell
surface.
The GP2b and GP4 proteins are type
I membrane glycoproteins, containing one and three functional
N-glycosylation sites, respectively
(11,
34). Both proteins
possess three luminal cysteine residues after signal sequence removal.
A fourth cysteine is located in the putative transmembrane segment of
the GP2b protein and in the endodomain of the GP4
protein. The GP3 protein is a heavily glycosylated integral
membrane protein with an uncleaved amino-terminal signal sequence and
nine cysteine residues. The protein is inserted into the lipid bilayer
by either or both of its hydrophobic terminal domains and has no parts
that are detectably exposed cytoplasmically
(15,
34).
In
EAV-infected cells, the GP2b protein occurs in four
monomeric conformations, which differ in their disulfide-bonded
structures (11). In
addition to these GP2b monomers, the GP2b protein
assembles into a heterotrimeric complex with the GP3 and
GP4 proteins
(33). Due to the low
stability of the GP2b/GP3/GP4 trimers,
only the covalently linked GP2b/GP4 complexes of
45 kDa are detected after analysis of lysates from EAV-infected cells
by immunoprecipitation and gel electrophoresis under nonreducing
conditions (33). The
minor envelope glycoproteins are incorporated into virions only as
GP2b/GP3/GP4 complexes, i.e.,
incorporation of one of them requires the presence of the others
(Wieringa et al., unpublished data). Interestingly, following the
release of virus particles from infected cells, GP3 becomes
disulfide linked to the GP2b/GP4 heterodimers,
resulting in the formation of a 66-kDa complex consisting of covalently
bound GP2b, GP3, and GP4 molecules. As
a consequence of this postassembly modification, two different
covalently linked GP2b complexes are observed in EAV
particles, i.e., GP2b/GP4 heterodimers and
GP2b/GP3/GP4 heterotrimers
(33) (Fig.
1).
Cystine bridges thus seem to play essential roles in the
formation, stabilization, and probably also the functioning of the
GP2b/GP3/GP4 trimers. We therefore
performed a mutational analysis of the luminal cysteines of the
GP2b protein by using the vaccinia virus-T7 RNA polymerase
transfection system in the context of a full-length infectious EAV cDNA
clone. These experiments established an important role for the cysteine
residues of the GP2b protein in virus infectivity and
allowed us to draw a model of the covalent interactions between the
minor envelope glycoproteins in the 45- and 66-kDa
complexes.
 |
MATERIALS AND
METHODS
|
|---|
Cells and antisera.
Baby hamster kidney (BHK-21 C13)
cells (American Type Culture Collection) were grown and maintained in
Glasgow minimal essential medium (GMEM; Invitrogen-Life Technologies)
supplemented with 10% heat-inactivated fetal bovine serum (FBS),
100 IU of penicillin per ml, and 100 µg of streptomycin per ml
(GMEM-10% FBS). The production and characterization of
rabbit antisera specific for the extreme carboxy termini of the EAV
GP2b and M proteins (raised against synthetic peptides
corresponding to residues 212 through 227 and 146 through 162 of the
respective proteins) have been reported earlier
(9).
Construction
of mutant ORF2b expression plasmids.
Recombinant DNA techniques were
performed essentially as described by Sambrook et al.
(23). The plasmids pAVI02
C48S, pAVI02 C102S, pAVI02 C137S, and pAVI02 C195S, which code for
cysteine-to-serine mutants of the EAV GP2b protein, were
constructed by oligonucleotide-mediated site-directed mutagenesis using
the method described by Kunkel et al.
(18). First, the 0.8-kb
BamHI-EcoRV fragment of plasmid pAVI02
(9) containing EAV ORF2b
was cloned into BamHI- and EcoRV-digested M13BM20
(Roche), yielding M13BM20-ORF2b. Next, uracil-containing
single-stranded DNA was prepared from M13BM20-ORF2b in the dut ung
Escherichia coli strain CJ236 (Roche). Five picomoles of the
mutagenic oligonucleotide 288, 289, 290, or 291 (Table
1) was then annealed to 1 µg of the single-stranded M13BM20-ORF2b
DNA in a total volume of 10 µl of 20 mM Tris-HCl (pH
7.5)-10 mM MgCl2-50 mM NaCl-1 mM
dithiothreitol (DTT). Before hybridization to the single-stranded DNA
template, the oligonucleotides were phosphorylated with bacteriophage
T4 polynucleotide kinase (Amersham Pharmacia Biotech). The annealing
products were converted into double-stranded covalently closed circles
by the addition of 20 µl of 20 mM Tris-HCl (pH 7.5)-10
mM MgCl2-10 mM DTT containing 1 mM ATP, 1 mM (each)
deoxynucleoside triphosphates, 5 U of bacteriophage T7 DNA polymerase
(Amersham Pharmacia Biotech), and 7 U of bacteriophage T4 DNA ligase
(Amersham Pharmacia Biotech) and incubation for 2 h at
37°C. The second-strand synthesis was terminated by the
addition of 1 µl of 0.5 M EDTA (pH 8.0), and the reaction
mixtures were used to transform E. coli strain PC2495
(Phabagen). Individual plaques were picked and mixed with 2 ml of
Luria-Bertani medium and 100 µl of an overnight culture of
PC2495. After incubation for 5 h at 37°C, with
constant agitation, single-stranded DNA was purified and subjected to
nucleotide sequence analysis with a bacteriophage T7 DNA polymerase
sequencing kit (Amersham Pharmacia Biotech) and
[
-35S]dATP (>1,000
Ci/mmol) (Amersham Pharmacia Biotech). Next, replicative-form
DNA was prepared from M13BM20-ORF2b clones carrying the intended point
mutations and incubated with BamHI and EcoRV. The
resulting 0.8-kb BamHI-EcoRV fragments containing the
mutant ORF2b sequences were purified from gels and inserted into
BamHI- and EcoRV-digested pBluescript KS(+)
(Stratagene), yielding pAVI02 C48S, pAVI02 C102S, pAVI02 C137S, and
pAVI02 C195S. In these plasmids, a bacteriophage T7 RNA polymerase
promoter sequence is positioned upstream of the (mutant) ORF2b for
expression studies by the vaccinia virus-T7 RNA polymerase transfection
system.
Construction of mutant
full-length EAV cDNA clones.
To generate full-length EAV cDNA
clones in which the codon for Cys-102 or Cys-137 of the GP2b
protein was changed to a serine codon, the 3.7-kb
BamHI-XhoI fragment of pEAV WT was inserted into
BamHI- and XhoI-digested pBluescript KS(+)
(Stratagene), creating pEAVBX-sh. The construct pEAV WT is a derivative
of the full-length infectious EAV cDNA clone pEAV030
(28) in which the
thymidylate corresponding to genome position 5117 of the EAV
untranslated repeat was replaced by a deoxycytidylate and
the sequence ACAATCTGTTTTCGTG at positions 8941 through 8956 was
replaced by the sequence CCAAAGCGTCTTCGTC to remove a
BamHI recognition site and a cryptic bacteriophage T7 RNA
polymerase terminator sequence, respectively. Next, the 0.4-kb
MscI-NsiI fragment of pAVI02 C102S and of pAVI02
C137S was cloned into MscI- and NsiI-digested
pEAVBX-sh. The 2.3-kb BamHI-EcoRI fragments of the
resulting plasmids were used to replace the corresponding fragment of
pEAV WT, generating pEAV GP2b C102S and pEAV GP2b
C137S, respectively.
To make the full-length EAV cDNA clone pEAV
GP2b C48S, which codes for a GP2b mutant carrying
a cysteine-to-serine substitution at amino acid position 48, the 1.3-kb
BamHI-SphI fragment of pEAV WT was inserted into
BamHI- and SphI-digested pUCBM20 (Roche), resulting
in pEAVBS-sh. The 0.3-kb EagI-SacI fragment of pAVI02
C48S was then cloned into EagI- and SacI-digested
pEAVBS-sh. The 1.3-kb BamHI-SphI fragment of the
resulting construct was inserted into the
BamHI-SphI-digested pEAVBX-sh. The 2.3-kb
BamHI-EcoRI fragment of the latter construct was
swapped into pEAV WT as described above to produce pEAV GP2b
C48S. For all these cloning steps, E. coli strain PC2495 was
used.
Independent expression studies
using the vaccinia virus-T7 RNA polymerase transfection
system.
Subconfluent
monolayers of BHK-21 C13 cells were washed with GMEM and inoculated
with vTF7.3, a recombinant vaccinia virus expressing the bacteriophage
T7 RNA polymerase gene, in GMEM for 50 min at 37°C at a
multiplicity of infection of
10 PFU per cell. The cells were
then washed with GMEM, subjected to treatment with Lipofectamine with
plasmid DNA as previously described
(33), and subsequently
incubated at 37°C. At 3 h postinfection (p.i.), 2 ml
of prewarmed GMEM-10% FBS was added to the
cells.
In vitro synthesis and
transfection of genome-length EAV RNA.
After digestion with XhoI,
the linearized plasmid DNAs were purified by phenol-chloroform
extraction, ethanol precipitated, and dissolved in water. The in vitro
transcription reactions were carried out by using the T7 mMESSAGE
mMACHINE kit (Ambion) according to the manufacturer's
instructions. After a 2-h incubation at 37°C, the mixtures were
kept on ice until the start of the transfection procedure. Confluent
monolayers of 2 x 107 BHK-21 cells were digested
with trypsin, resuspended in GMEM, and pelleted at 400 x
g for 5 min. The cells were washed twice in phosphate-buffered
saline (PBS) containing 50 mM CaCl2 and 50 mM
MgCl2 (PBS Ca/Mg) and resuspended in 800 µl of PBS
Ca/Mg. A 10-µl aliquot of the transcription mixture was added
to the cell suspension, which was then transferred into electroporation
cuvettes (BTX) with a 4-mm gap size. The cells were pulsed twice at 850
V and 50 µF, with the pulse controller set at
"infinite." The cells were resuspended in
GMEM-10% FBS, seeded into 10-cm2 wells, and
incubated at 39°C.
Metabolic
labeling of intracellular proteins.
At the indicated time points after
transfection, the cells were washed with PBS and incubated in prewarmed
starvation medium (Dulbecco's modified Eagle's medium without
L-cysteine and L-methionine [Invitrogen-Life
Technologies] supplemented with 5% dialyzed FBS and 10 mM
HEPES-KOH [pH 7.4]). Following an incubation period of 30
min, 80 µCi of
L-[35S]methionine (ICN) was added per
10-cm2 culture dish and the cells were labeled at
37°C (independent expression studies) or 39°C (EAV RNA
transfection experiments) for the indicated times. Alternatively, the
cells were incubated in starvation medium containing 0.2 mM
L-methionine and labeled with 80 µCi of
L-[35S]cysteine (ICN) instead of
L-[35S]methionine. After the labeling
period, the cells were put on ice and washed with ice-cold PBS
containing 50 mM CaCl2, 50 mM MgCl2, and, to
block reactive thiol groups, 20 mM N-ethylmaleimide (NEM;
Sigma-Aldrich) or 50 mM iodoacetamide (IAM; Sigma-Aldrich) as indicated
in the figure legends. Next, the cells were lysed in ice-cold lysis
buffer (20 mM Tris-HCl [pH 7.6], 150 mM NaCl, 1%
Nonidet P-40, 0.5% sodium deoxycholate, 0.1% sodium
dodecyl sulfate [SDS]) supplemented with 1 µg each of
aprotinin, leupeptin, and pepstatin A per ml and containing either 20
mM NEM or 50 mM IAM. The cell lysate was cleared by centrifugation for
15 min at 14,000 rpm in a microcentrifuge. The pellet was discarded,
and the supernatant was supplemented with EDTA to a final concentration
of 5 mM.
Preparation of radiolabeled
viral particles.
BHK-21 C13
cells were transfected with synthetic EAV RNAs and labeled at
7 h posttransfection (p.t.) with
L-[35S]methionine or
L-[35S]cysteine as described above.
After a 12-h labeling period at 39°C, the culture supernatant
was harvested and the cell debris was removed by low-speed
centrifugation (10 min at 4,000 rpm and room temperature in a
microcentrifuge). The viral particles were then pelleted through a
cushion of 20% (wt/wt) sucrose in 20 mM Tris-HCl (pH
7.6)-20 mM MgCl2 by centrifugation for 2 h
in an SW 50.1 rotor (Beckman) at 28,000 rpm and 4°C. The
resulting pellet was dissolved in 1 ml of ice-cold lysis buffer
containing 20 mM NEM and further processed as a true cell
lysate.
Immunoprecipitation and gel
electrophoresis.
Proteins
were immunoprecipitated from cell lysates and dissolved virions and
analyzed in SDS-15% polyacrylamide (PAA) gels as
described previously
(33). The samples were
heated for 5 min at 95°C before being applied to the gels,
except for immunoprecipitates prepared with the M-specific antiserum
(
M), which were analyzed without heating to avoid aggregation
of the EAV M and GP5 proteins. After electrophoresis, the
gels were processed for fluorography as previously reported
(34) and exposed at
-80°C to Kodak X-ray films or, for quantitative
analyses, to storage phosphorimaging plates (Molecular
Dynamics).
Sucrose density
gradients.
[35S]cysteine-labeled
EAV particles were concentrated through a 20% (wt/wt) sucrose
cushion, as described above. The resulting pellet was gently
resuspended in TM buffer (20 mM Tris-HCl [pH 7.0], 20 mM
MgCl2). Next, a 400-µl aliquot of the virus
suspension was carefully mixed with 1.2 ml of 67% (wt/wt)
sucrose in TM buffer. A 10 to 50% (wt/wt) sucrose gradient was
then prepared by overlaying the virus-sucrose mixture with 5.4 ml of
40% (wt/wt), 2 ml of 35% (wt/wt), 1 ml of 30%
(wt/wt), and finally 1.5 ml of 10% (wt/wt) sucrose in TM buffer.
The gradient was subjected to centrifugation for 36 h at
36,000 rpm and 4°C with an SW41 rotor (Beckman) and was
collected in 12 serial fractions of approximately 1 ml from the top of
the centrifugation tube. The different fractions were transferred to
SW50.1 tubes and diluted with TM buffer to a final volume of 4 ml.
Virus particles present in these fractions were subsequently pelleted
by centrifugation for 1 h at 24,000 rpm and 4°C with
an SW50.1 rotor (Beckman). The resulting pellets were dissolved in 1 ml
of ice-cold lysis buffer containing 20 mM NEM and further processed as
described above. The EAV particles ended up in fractions 4 through 6,
as determined by 50% tissue culture infective dose
(TCID50) assay and by immunoprecipitation analysis using a
GP5-specific rabbit antiserum
(10).
 |
RESULTS
|
|---|
Disulfide-bonded
structure of the GP2b monomers.
It was previously shown by SDS-PAA gel
electrophoresis (SDS-PAGE) under nonreducing conditions that the
GP2b protein adopts four different monomeric conformations
when expressed by a recombinant vaccinia virus vector or in
EAV-infected cells (11).
The three fastest migrating of these monomeric forms most likely
contain different intrachain disulfide bonds, since under reducing
conditions the GP2b protein migrates as a single band and
has the same electrophoretic mobility as the slowest migrating
GP2b species resolved under nonreducing conditions
(11).
To
investigate the folding of the GP2b protein in more detail,
we infected BHK-21 cells with vTF7.3 and transfected them with plasmids
directing the synthesis of the wild-type GP2b protein or of
the GP2b cysteine mutants GP2b C48S,
GP2b C102S, GP2b C137S, and GP2b
C195S. In each of these GP2b mutants, one of the cysteine
residues downstream of the signal sequence was replaced by a serine
residue. At 4 h p.i., the proteins in the cells were
metabolically labeled with [35S]methionine for 15
min. Next, the cells were dissolved in lysis buffer containing a 50 mM
concentration of the alkylating agent IAM, immunoprecipitations with a
GP2b-specific antiserum (
GP2b) were
performed, and the immunoprecipitates were analyzed in an
SDS-15% PAA gel under nonreducing conditions. Under
these conditions, both the wild-type GP2b protein and the
GP2b C195S mutant showed the familiar pattern of four
distinct monomeric conformations (Fig.
2). The other three GP2b mutants each displayed a unique pattern
of two bands. For the GP2b C102S mutant, the fastest
migrating of its two folding variants had a very similar
electrophoretic mobility as the fastest migrating form of the wild-type
GP2b protein. The most compact of the GP2b C48S
and GP2b C137S species comigrated with the second fastest
and second slowest migrating forms of the wild-type GP2b
protein, respectively. The slowest migrating form of all mutant
GP2b proteins comigrated with that of wild-type
GP2b and hence must lack intramolecular disulfide bridges.
The subtle differences in electrophoretic mobility between
corresponding forms of the wild-type and mutant GP2b
proteins are most likely direct consequences of the cysteine-to-serine
mutations. These results confirm that the multiple band appearance of
the GP2b protein under nonreducing conditions is indeed due
to the formation of different intrachain disulfide bonds between the
luminal cysteine residues and allow us to assign a specific disulfide
bridge to three of the four monomeric forms, as depicted in Fig.
7A.

View larger version (40K):
[in this window]
[in a new window]
|
FIG. 2. Conformational
variants of the GP2b monomers. vTF7.3-infected BHK-21 C13
cells were transfected with plasmids encoding the wild-type
GP2b protein or the GP2b cysteine mutants. At
4 h p.i., the cells were labeled for 15 min with
[35S]methionine. Next, cell lysates were prepared
in the presence of IAM and immunoprecipitations were performed with
GP2b. The immunoprecipitates were analyzed under
nonreducing conditions in an SDS-15% PAA gel. The
arrowheads indicate the positions of the different GP2b
conformations. The values on the left are the molecular sizes, in
kilodaltons, of marker proteins analyzed in the same
gel.
|
|

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 7. Disulfide-bonded
structure of the GP2b monomers and the disulfide-bonded
GP2b/GP3/GP4 heterotrimers.
(A) Disulfide-bonded structures of each of the
GP2b monomeric forms resolved by SDS-PAGE under nonreducing
conditions are shown. (B) Two alternative models for the
disulfide-bonded structure of the covalently linked
GP2b/GP3/GP4 heterotrimers are drawn.
The only difference between these models is the membrane topology of
the GP3 protein, which is currently unknown. Since the
disulfide-bonded structures of the GP3 and GP4
proteins have not yet been determined, the positions of the interchain
cystine bridges relative to the ectodomains of these proteins are
arbitrary. Disulfide bonds are indicated by dotted lines. The boxes
symbolize the predicted transmembrane domains and the circles represent
N-linked oligosaccharide side
chains.
|
|
Fate
of the GP2b cysteine mutants in cells transfected with
synthetic full-length EAV RNAs.
In EAV-infected cells, the
GP2b protein occurs in a multimeric complex with the
GP3, GP4, and possibly E proteins
(33). Due to the low
stability of this complex, only disulfide-linked
GP2b/GP4 heterodimers are detected after SDS-PAGE
under nonreducing conditions
(33). To study the role
of the luminal cysteine residues of the GP2b protein in
complex formation with GP3 and GP4 as well as
their significance for virus infectivity, the GP2b mutations
C48S, C102S, and C137S were introduced into a full-length EAV cDNA
clone. The GP2b C195S mutant was not included in this study,
as Cys-195 resides in the transmembrane domain of GP2b and
is therefore most likely not involved in intermolecular disulfide bond
formation. Moreover, its cloning was hampered by the overlap of the
3' end of ORF2b with the 5' end of ORF3 in the viral
genome.
First, we investigated the intracellular fate of the
GP2b cysteine mutants. BHK-21 cells were transfected with in
vitro transcripts of the full-length EAV cDNA clones pEAV WT, pEAV
GP2b C48S, pEAV GP2b C102S, pEAV GP2b
C137S, and pEAV KO2b. The latter construct, in which the
GP2b gene is inactivated by a point mutation in its
initiation codon (24),
served as a negative control. At 7 h p.t., the cells were
labeled for 12 h with [35S]methionine,
after which the cells were in a progressive state of cytopathic effect.
Following lysis of the cells, the GP2b protein was
immunoprecipitated with
GP2b and analyzed by
SDS-PAGE under reducing and nonreducing conditions (Fig.
3).

View larger version (59K):
[in this window]
[in a new window]
|
FIG. 3. Fate
of the GP2b cysteine mutants in cells transfected with
synthetic full-length EAV RNAs. BHK-21 C13 cells were mock transfected
or transfected with in vitro transcripts of the full-length EAV cDNA
clone pEAV WT, pEAV GP2b C48S, pEAV GP2b C102S,
pEAV GP2b C137S, or pEAV KO2b. At 7 h p.t., the
cells were labeled with [35S]methionine for
12 h. Next, cell lysates were prepared in the presence of NEM
and immunoprecipitations were performed with GP2b
or the corresponding preimmune serum. The immunoprecipitates were
analyzed in SDS-15% PAA gels under reducing
(+DTT) and nonreducing (-DTT) conditions. The values on
the left are the molecular sizes, in kilodaltons, of marker proteins
analyzed in the same gel. The positions of the N protein, the
GP2b monomers, and the disulfide-linked
GP2b/GP4 heterodimers are indicated on the
right.
|
|
Not only the GP2b but also the N protein was
precipitated from each of the cell lysates (Fig.
3; +DTT). The N
protein is not coprecipitated through an interaction with the
GP2b protein but binds directly to the Staphylococcus
aureus cells used to collect the specific immune complexes
(27) (lanes KO2b and WT
preserum). Quantitative analysis of the part of the gel corresponding
to the left half of Fig. 3
yielded comparable GP2b/N ratios for pEAV WT, pEAV
GP2b C48S, pEAV GP2b C102S, and pEAV
GP2b C137S, indicating that the cysteine-to-serine mutations
did not markedly alter the stability of the GP2b protein.
When analyzed under nonreducing conditions (Fig.
3; -DTT), the four
monomeric forms of the wild-type GP2b protein and the two
typical monomeric conformations of the GP2b mutants C48S,
C102S, and C137S were again observed, though they were less distinct
than in the previous experiment. This is largely due to the use of NEM
instead of IAM as the sulfhydryl-modifying agent
(7). In addition, the
45-kDa GP2b-containing complex was clearly observed in the
sample derived from the pEAV WT RNA-transfected cells. Recently, we
established that this 45-kDa complex is a covalently linked
GP2b/GP4 heterodimer
(33) rather than a
disulfide-bonded GP2b/GP2b homodimer
(11). Due to protein
maturation, these GP2b/GP4 heterodimers appear as
a doublet (11). Also,
from lysates of cells transfected with pEAV GP2b C48S or
pEAV GP2b C137S RNA, protein species were precipitated with
an electrophoretic mobility similar to that of the
GP2b/GP4 heterodimers, but the fraction of
GP2b present in these complexes was relatively small. As
discussed below, the single-band appearance of these complexes probably
results from a block in the formation of intrachain disulfide bonds in
GP2b C48S and GP2b C137S and a concomitant change
in the processing of one or more of the N-linked oligosaccharide side
chains attached to the GP2b/GP4 heterodimers. No
covalently linked GP2b/GP4 proteins were observed
in cells transfected with pEAV GP2b C102S RNA. These
observations suggest that Cys-102 of GP2b is involved in the
formation of the cystine bridge with the GP4
protein.
Particle formation by EAV
GP2b cysteine mutants.
Recently, we demonstrated that
GP5, M, and N are the only EAV proteins required for the
production of viral particles. In the absence of any one of these
proteins, no viral particles are assembled and no structural proteins
are released into the culture supernatants of infected cells (Wieringa
et al., unpublished data). To investigate the effect of the
cysteine-to-serine mutations in GP2b on virion formation, we
transfected BHK-21 cells with synthetic RNAs of the different
full-length EAV cDNA clones as described above and labeled them with
[35S]methionine for 12 h. The
particulate material in the culture supernatants was then concentrated
by sedimentation through a 20% (wt/wt) sucrose cushion,
dissolved in lysis buffer, and incubated with
M antibodies. In
the absence of a reducing agent, this antiserum precipitates M
monomers, M homodimers, and GP5/M heterodimers
(10). The resulting
immune complexes were analyzed by SDS-PAGE under reducing conditions.
As shown in Fig.
4, the GP5, M, and N proteins were present in all samples, with
the exception of the control sample derived from mock-transfected
BHK-21 cells. Apparently, each of the synthetic full-length EAV RNAs
directed the formation of viral particles, indicating that the
mutations in the GP2b protein did not interfere with
particle assembly.

View larger version (65K):
[in this window]
[in a new window]
|
FIG. 4. Particle
formation by the EAV GP2b cysteine mutants. BHK-21 C13 cells
were mock transfected or transfected with in vitro transcripts of the
full-length EAV cDNA clone pEAV WT, pEAV GP2b C48S, pEAV
GP2b C102S, pEAV GP2b C137S, or pEAV KO2b. At
7 h p.t., the cells were labeled with
[35S]methionine for 12 h. After removal
of cell debris by low-speed centrifugation, the viral particles present
in the cell culture medium were pelleted through a cushion of
20% (wt/wt) sucrose. The pellets were then dissolved in lysis
buffer and subjected to immunoprecipitation with M antibody.
The immunoprecipitates were analyzed under reducing conditions in an
SDS-15% PAA gel. The values on the left are the
molecular sizes, in kilodaltons, of marker proteins analyzed in the
same gel. The positions of the EAV GP5, M, and N proteins
are indicated on the
right.
|
|
Composition of EAV
GP2b cysteine mutant particles.
Next, we determined whether the viral
particles purified from the culture supernatants of cells transfected
with pEAV GP2b C48S, pEAV GP2b C102S, or pEAV
GP2b C137S RNA contained (mutant) GP2b proteins.
To this end, aliquots of the extracellular protein preparations from
the previous experiment were subjected to immunoprecipitation with
GP2b in the presence of 5 mM DTT. Analysis by
SDS-PAGE under reducing conditions revealed the presence of clearly
detectable, albeit different, amounts of the GP2b protein in
the viral particles released from cells that had received pEAV WT, pEAV
GP2b C48S, pEAV GP2b C102S, or pEAV
GP2b C137S RNA. As expected, no GP2b molecules
were detected in the sample derived from pEAV KO2b RNA-transfected
cells (Fig.
5A). To more closely study the efficiency with which different
GP2b proteins are incorporated into EAV particles, we
determined the GP2b/N ratio of each sample by phosphorimager
analysis of the gel depicted in Fig.
5A. As shown in Fig.
5B, the viral particles
obtained with pEAV GP2b C48S and pEAV GP2b C137S
contained about 10 times less GP2b protein than the virions
released from pEAV WT RNA-transfected cells. The GP2b
content of the viral particles secreted by pEAV GP2b C102S
RNA-transfected cells was approximately fourfold lower than that of
wild-type EAV particles. Reproduction of this experiment yielded
essentially the same results.

View larger version (37K):
[in this window]
[in a new window]
|
FIG. 5. Incorporation
of the EAV GP2b cysteine mutants into viral particles.
(A) [35S]methionine-labeled viral
particles were produced, concentrated, and dissolved in lysis buffer as
described in the legend for Fig.
4. Subsequently,
immunoprecipitations were performed with GP2b or
the corresponding preimmune serum in the presence of 5 mM DTT. The
immunoprecipitates were analyzed under reducing conditions in an
SDS-15% PAA gel. The values on the left are the
molecular sizes, in kilodaltons, of marker proteins analyzed in the
same gel. The positions of the EAV GP2b and N proteins are
indicated on the right. (B) The amounts of radiolabel
incorporated into the EAV GP2b and N proteins were
determined by phosphorimager analysis. Subsequently, the
GP2b/N ratio was calculated and plotted, setting the ratio
obtained for the wild-type virus at
100.
|
|
Complexes of
the minor envelope glycoproteins in EAV GP2b cysteine mutant
particles.
In EAV particles,
the GP2b protein occurs in a complex with GP3 and
GP4. To study the role of the luminal cysteine residues of
the GP2b protein in the formation of this complex, we again
prepared radiolabeled viral particles, using the wild-type and mutant
full-length EAV cDNA clones. To improve the detection of the
GP3 and GP4 proteins, we performed the labeling
procedure with [35S]cysteine instead of
[35S]methionine. The solubilized virus particles
were incubated with
GP2b and the resulting
immunoprecipitates were analyzed by SDS-PAGE under reducing and
nonreducing conditions.
As shown in Fig.
6 (-DTT), the protein profiles obtained after analysis under
nonreducing conditions were similar for EAV WT, EAV GP2b
C48S, and EAV GP2b C137S. In all cases, covalently linked
GP2b/GP4 dimers and
GP2b/GP3/GP4 trimers were observed,
though the complexes containing the mutant GP2b proteins
migrated slightly slower than those comprising wild-type
GP2b. In contrast, neither of these complexes was observed
in viral particles produced by pEAV GP2b C102S
RNA-transfected cells. Instead, a single protein species of 23 kDa was
detected, with apparently the same electrophoretic mobility as the
GP2b monomeric species inferred to contain an intramolecular
disulfide bond between Cys-48 and Cys-137 (cf. Fig.
2,
3, and
8). The latter observation
indicates that the GP2b species lacking Cys-102 is
incorporated into viral particles but does not form a cystine bridge
with GP4 and/or GP3.

View larger version (44K):
[in this window]
[in a new window]
|
FIG. 6. Complexes
of the minor envelope glycoproteins in GP2b cysteine mutant
particles. Radiolabeled viral particles were produced, concentrated,
and dissolved in lysis buffer as described in the legend for Fig.
4, except that the
proteins were labeled with [35S]cysteine rather
than [35S]methionine. Subsequently,
immunoprecipitations were performed with GP2b or
the corresponding preimmune serum. The immunoprecipitates were analyzed
in SDS-15% PAA gels under reducing (+DTT) and
nonreducing (-DTT) conditions. The values on the left are the
molecular sizes, in kilodaltons, of marker proteins analyzed in the
same gel. The positions of the GP2b, GP3, and
GP4 monomers and the disulfide-linked
GP2b/GP4 heterodimers and
GP2b/GP3/GP4 heterodimers are
indicated on the
right.
|
|

View larger version (12K):
[in this window]
[in a new window]
|
FIG. 8. Infectivity
of the EAV GP2b cysteine mutant particles. BHK-21 C13 cells
were transfected with synthetic RNAs transcribed from pEAV WT, pEAV
KO2b, pEAV GP2b C48S, pEAV GP2b C102S, or pEAV
GP2b C137S. Next, the infectious titers in the culture
supernatants of these cells at 15 and 40 h p.t. were
determined by end-point dilution. Times p.t. (in hours) are indicated
on the abscissa, while TCID50 values (in infectious units
per milliliter) are plotted on the
ordinate.
|
|
Also, under reducing
conditions similar protein patterns were seen for EAV WT, EAV
GP2b C48S, and EAV GP2b C137S (Fig.
6, +DTT). The two
characteristic species of 38 and 42 kDa correspond to the
GP3 protein, while the 28-kDa product represents the
GP4 protein
(34). Under reducing
conditions, relatively little GP3 seems to be recovered
compared to GP2b or GP4. It should be noted,
however, that the GP3 protein originates from the
disulfide-bonded GP2b/GP3/GP4
heterotrimers only, while the GP2b and GP4
proteins are derived from both the GP2b/GP4 and
GP2b/GP3/GP4 complexes. Moreover, when
analyzed under reducing conditions, the GP3 protein migrates
as two species due to variable glycosylation
(34). Since
GP3 and GP4 molecules were not coprecipitated
with the GP2b protein using the material derived from pEAV
GP2b C102S-transfected cells, GP2b Cys-102 must
be involved in the formation of the disulfide bond with the
GP4 protein. The other two luminal cysteine residues of
GP2b seem not to be involved in intermolecular disulfide
bond formation between the minor envelope glycoproteins, consistent
with our earlier interpretation that these residues form an
intramolecular cystine bridge. This is further supported by the
slightly reduced electrophoretic mobilities of the
GP2b/GP4 and
GP2b/GP3/GP4 complexes in EAV
GP2b C48S and EAV GP2b C137S particles compared
to those in the wild-type virus. In addition, the single-band
appearance of the covalently linked GP2b/GP4
dimers in cells transfected with pEAV GP2b C48S or pEAV
GP2b C137S RNA (Fig.
3) could be explained by
the absence of an intrachain disulfide in GP2b C48S and
C137S.
Both GP2b C48S and GP2b C137S are
able to form cystine-linked
GP2b/GP3/GP4 heterotrimers. This
implies that the covalent interaction of the disulfide-bonded
GP2b/GP4 dimers with the GP3 protein
in the GP2b/GP3/GP4 complex has to
occur through the GP4 protein. A schematic model for the
disulfide-bonded structure in EAV particles of the covalently linked
GP2b/GP3/GP4 trimers is presented in
Fig.
7. This model is based on the assumption that the covalent
association of GP3 with the disulfide-bonded
GP2b/GP4 dimers does not affect the
intramolecular cystine bridge in
GP2b.
Infectivity of the EAV
GP2b cysteine mutant particles.
To investigate whether the viral
particles generated with the mutant full-length EAV cDNA clones were
infectious, BHK-21 cells were transfected with synthetic RNAs
transcribed from pEAV WT, pEAV KO2b, pEAV GP2b C48S, pEAV
GP2b C102S, or pEAV GP2b C137S. An aliquot of the
cells was seeded on glass coverslips and processed for
immunofluorescence at 15 h p.t. Labeling with
M
antibodies indicated that a transfection efficiency of approximately
90% had been achieved in each case (data not shown). The rest of
the cells were transferred to dishes. The infectious titers in the
culture supernatants of these dishes at 15 and 40 h p.t. were
determined by end-point dilution (Fig.
8). At 15 h p.t., the titer in the culture supernatant of pEAV WT
RNA-transfected cells was approximately 2 x 107
TCID50/ml. This titer decreased to 6.3 x
106 TCID50/ml at 40 h p.t. EAV
GP2b C48S and EAV GP2b C137S showed comparable
growth kinetics but reached much lower maximum titers (between 3
x 103 and 2 x104
TCID50/ml) than the wild-type virus. No infectivity was
found in the culture supernatants of the cells transfected with pEAV
GP2b C102S or pEAV KO2b
RNA.
 |
DISCUSSION
|
|---|
The EAV GP2b
protein is a typical class I membrane glycoprotein, containing three
cysteine residues in its ectodomain and one in its transmembrane anchor
(7,
11). In EAV-infected
cells, the bulk of the GP2b molecules are present as four
different monomeric species while a small fraction occurs in a
heteromeric complex with GP3 and GP4
(33). Only this
heteromeric complex appears in virus particles, albeit in relatively
small amounts, whereas the GP2b monomers stay behind in the
endoplasmic reticulum of the infected cells. It was already clear from
previous experiments performed in our laboratory
(11) that disulfide bonds
are involved in the formation of the different GP2b monomers
and the GP2b-containing heterooligomers. In this study, the
importance of the intra- and intermolecular disulfide bonds of the
GP2b protein for the assembly of complete and infectious
virus particles was demonstrated by use of cysteine-to-serine mutants
of the GP2b protein.
Expression of the ORFs coding for
these GP2b cysteine mutants from plasmids or full-length EAV
cDNA clones confirmed that three of the four monomeric GP2b
species contained alternative intrachain disulfide bonds between the
luminal cysteine residues. As might perhaps be expected from a linkage
bringing together distant parts of a polypeptide, the most compacted
and thus fastest migrating GP2b monomers possess a disulfide
bond between Cys-48 and Cys-137. This simplification does not hold for
the other monomeric forms of GP2b, as the species with the
linkage between Cys-48 and Cys-102 (54 residues apart) runs slower than
the protein in which Cys-102 and Cys-137 (35 residues apart) are
connected. The fully reduced molecule has the lowest electrophoretic
mobility.
The data obtained with the full-length EAV cDNA clones
encoding GP2b cysteine mutants resulted in a model for the
intra- and intermolecular disulfide bonds of the GP2b
protein (Fig. 7B). In this
model, GP2b Cys-102 is responsible for the cystine bridge
with the GP4 protein while an intrachain disulfide bond
links Cys-48 and Cys-137 of GP2b. The structure proposed in
Fig. 7B is primarily based
on the observation that both EAV GP2b C48S and EAV
GP2b C137S particles contained disulfide-bonded
GP2b/GP4 dimers as well as disulfide-bonded
GP2b/GP3/GP4 trimers but that neither
of these complexes was present in GP2b C102S mutant
particles. Furthermore, the electrophoretic mobility under nonreducing
conditions of the GP2b C102S molecules that were
incorporated into viral particles corresponded with that of the
GP2b monomers containing an intramolecular cystine bridge
between Cys-48 and Cys-137. Finally, the single-band appearance of the
covalently linked GP2b/GP4 dimers extracted from
cells transfected with pEAV GP2b C48S or pEAV
GP2b C137S RNA and the slightly lower electrophoretic
mobility of the heteromeric complexes in virus particles comprising
GP2b C48S and GP2b C137S than of those in virus
particles containing the wild-type GP2b protein are,
presumably, both the result of the absence of intrachain disulfide
bonds in these GP2b mutants.
In our model, all luminal
cysteine residues of GP2b are used for the formation of
intra- and interchain disulfide bonds. This implies that the covalent
association of GP3 with the cystine-linked
GP2b/GP4 heterodimer occurs via the
GP4 protein. In this respect, it is interesting that we
recently obtained preliminary evidence for the presence in EAV
GP2b C102S particles of a protein species with an apparent
molecular mass compatible with that of a covalently bound
GP3/GP4 heterodimer (data not shown). It is at
present difficult to assign the cysteine residues that are involved in
the intermolecular disulfide bond formation between GP4 and
GP3. All three luminal cysteines of GP4 and most
of the nine cysteines of GP3 are conserved among the
sequenced EAV isolates
(1). Likewise, we do not
know which cysteine residue in GP4 interacts with Cys-102 of
GP2b. The GP2b protein of EAV has many features
in common with its homologs in other arteriviruses. Each of these
proteins seems to be a class I membrane protein
(13), and the relative
positions of their luminal cysteine residues, N-glycosylation sites,
and transmembrane anchors are highly conserved
(14). However, the
GP2 and VP-3 M proteins of PRRSV and LDV, respectively, do
not contain an EAV GP2b Cys-102 counterpart. Little is known
about complex formation of the EAV GP2b, GP3, and
GP4 homologs in other arteriviruses. It has been reported
that the GP4 protein of the IAF-Klop strain of PRRSV is
coprecipitated with the GP3 protein from lysates of
virus-infected cells (20)
and that the GP2 protein of the Lelystad strain of PRRSV
occurs in virions only in its fully reduced conformation
(21). In contrast,
approximately half of the GP2 molecules present in lysates
of PRRSV-infected CL2621 cells contain an intramolecular disulfide
bond. The intrachain disulfide bond in the GP2 protein of
PRRSV particles may hence have been lost during the analytical
procedures. Nevertheless, these observations do not exclude the
existence of noncovalently linked complexes of the minor envelope
glycoprotein in these viruses. Especially given the crucial role of EAV
GP2b Cys-102 in the formation of the disulfide-bonded
GP2b/GP4 dimers and
GP2b/GP3/GP4 trimers and the absence
of this residue from the GP2 proteins of LDV and PRRSV,
covalently linked heterotrimeric complexes of the minor envelope
glycoproteins are not expected for the latter viruses.
The
different cysteine-to-serine mutations introduced into the
GP2b protein did not hamper the assembly of viral particles,
i.e., similar amounts of GP5, M, and N were detected in the
culture supernatants of cells transfected with synthetic RNAs
transcribed from pEAV WT, pEAV GP2b C48S, pEAV
GP2b C102S, or pEAV GP2b C137S. Nonetheless, the
amino acid substitutions resulted in a reduced incorporation of the
GP2b protein into viral particles, i.e., EAV GP2b
C48S and EAV GP2b C137S particles each contained
approximately 10 times less GP2b protein than the wild-type
virus. Thus, the cysteine-to-serine mutations at positions 48 and 137
of the GP2b protein not only have a similar effect on the
generation of the intrachain disulfide bond and the covalently linked
GP2b/GP4 heterodimer but also affect the
incorporation of these complexes into virions. It is quite plausible
that the formation of disulfide-bonded GP2b/GP4
heterodimers is a limiting step in the assembly of complete virus
particles. This seems, however, in conflict with the observation that
GP2b C102S does not covalently interact with the
GP4 protein but is nevertheless present in larger amounts in
virions than the other two GP2b mutants. Obviously, the
C102S mutation has a less dramatic effect on the conformation of
GP2b, and the GP2b C102S molecules incorporated
into virus particles are likely to be associated with the
GP4 protein in a noncovalent way. The incorporation of
GP3 and GP4 in EAV GP2b C102S
particles would be consistent with a previous observation that the
inclusion of the GP2b protein into virus particles requires
the GP3, GP4, and E proteins (Wieringa et al.,
unpublished data). Unfortunately, because of the high background
signals obtained with the GP3- and GP4-specific
antisera, we were unable to clearly detect the probably rather small
amounts of GP3 and GP4 monomers in EAV
GP2b C102S particles.
In view of these considerations,
it was remarkable that EAV GP2b C102S particles were
noninfectious. Apparently the disulfide bond between GP2b
and GP4 is an absolute requirement for the functioning of
the GP2b/GP3/GP4/(E) complex. As we
argued before, this complex is most likely involved in viral targeting
and cell entry. Conversely, EAV GP2b C48S and EAV
GP2b C137S particles exhibited a low but significant level
of infectivity even though they contain less of the GP2b
protein than the EAV GP2b C102S particles. This infectivity,
which was remarkably similar for both mutants, might be due to
reversion of the mutation. However, we find this possibility very
unlikely, since all GP2b cysteine mutants were generated by
U-to-A transversions and no infectivity was found in the culture
supernatant of cells transfected with pEAV GP2b C102S or
pEAV KO2b RNA. The 3-log difference in infectivity between EAV
GP2b C48S or EAV GP2b C137S particles and the
wild-type virus was not proportional to their approximately 10-fold
difference in GP2b content. There are many possible reasons
for this apparent discrepancy; one interpretation is that the
intramolecular disulfide bond in GP2b is also important for
the functioning of the
GP2b/GP3/GP4/(E) complex. However, as
the GP2b protein is not essential for viral RNA replication
and transcription (22,
24), it is unlikely that
the point mutations introduced by us directly affected EAV replication
instead of being related to the biosynthesis, folding, and
incorporation into virus particles of the minor envelope glycoproteins
of EAV. The unraveling of this function is one of the major challenges
of future arterivirus research.
 |
ACKNOWLEDGMENTS
|
|---|
We are grateful to
Catherine Saunier for technical assistance. In addition, we thank
Bernard Moss for providing the recombinant vaccinia virus vTF7.3 and
Eric Snijder for making available the full-length EAV cDNA clones pEAV
WT and pEAV
KO2b.
 |
FOOTNOTES
|
|---|
* Corresponding
author. Mailing address: Department of Infectious Diseases and
Immunology, Virology Division, Utrecht University, Yalelaan 1, 3584 CL
Utrecht, The Netherlands. Phone: 31-30-2532462. Fax: 31-30-2536723.
E-mail:
p.rottier{at}vet.uu.nl. 
Present
address: Gene Therapy Section, Department of Molecular Cell Biology,
Leiden University Medical Center (LUMC), 2333 AL Leiden, The
Netherlands. 
Present
address: Gaubius Laboratory, TNO-PG, 2333 CK Leiden, The
Netherlands. 
 |
REFERENCES
|
|---|
- Archambault,
D., G. Laganière, and G. St.-Laurent. 1998.
Genetic variation and phylogenetic analysis of open reading frames 3
and 4 of various equine arteritis virus isolates. Adv. Exp. Med.
Biol.
440:813-819.[Medline]
- Cavanagh,
D. 1997. Nidovirales: a new order comprising
Coronaviridae and Arteriviridae. Arch.
Virol.
142:629-633.[Medline]
- Cowley,
J. A., C. M. Dimmock, K. M. Spann, and
P. J. Walker. 2000. Gill-associated virus of
Penaeus monodon prawns: an invertebrate virus with ORF1a and
ORF1b genes related to arteri- and coronaviruses. J.
Gen. Virol.
81:1473-1484.[Abstract/Free Full Text]
- Cowley,
J. A., C. M. Dimmock, and P. J.
Walker. 2002. Gill-associated nidovirus of Penaeus
monodon prawns transcribes 3'-coterminal subgenomic mRNAs
that do not possess 5'-leader sequences. J.
Gen. Virol.
83:927-935.[Abstract/Free Full Text]
- den
Boon, J. A., M. F. Kleijnen, W.
J. M. Spaan, and E. J. Snijder.1996
. Equine arteritis virus subgenomic mRNA synthesis:
analysis of leader-body junctions and replicative-form RNAs.J. Virol.
70:4291-4298.[Abstract]
- den
Boon, J. A., E. J. Snijder, E. D.
Chirnside, A. A. F. de Vries, M. C.
Horzinek, and W. J. M. Spaan.1991
. Equine arteritis virus is not a togavirus but
belongs to the coronaviruslike superfamily. J.
Virol.
65:2910-2920.[Abstract/Free Full Text]
- de
Vries, A. A. F. 1994. The
molecular biology of equine arteritis virus. Ph.D. thesis. Utrecht
University, Utrecht, The
Netherlands.
- de
Vries, A. A. F., E. D. Chirnside,
P. J. Bredenbeek, L. A. Gravestein, M. C.
Horzinek, and W. J. M. Spaan.1990
. All subgenomic mRNAs of equine arteritis virus
contain a common leader sequence. Nucleic Acids Res.
18:3241-3247.[Abstract/Free Full Text]
- de
Vries, A. A. F., E. D. Chirnside,
M. C. Horzinek, and P. J. M. Rottier.1992
. Structural proteins of equine arteritis virus.J. Virol.
66:6294-6303.[Abstract/Free Full Text]
- de
Vries, A. A. F., S. M. Post, M.
J. B. Raamsman, M. C. Horzinek, and P.
J. M. Rottier. 1995. The two major envelope
proteins of equine arteritis virus associate into disulfide-linked
heterodimers. J. Virol.
69:4668-4674.[Abstract]
- de
Vries, A. A. F., M. J. B.
Raamsman, H. A. van Dijk, M. C. Horzinek, and
P. J. M. Rottier. 1995. The small
envelope glycoprotein (GS) of equine arteritis virus folds
into three distinct monomers and a disulfide-linked dimer.J. Virol.
69:3441-3448.[Abstract]
- Dobbe,
J. C., Y. van der Meer, W. J. M. Spaan,
and E. J. Snijder. 2001. Construction of
chimeric arteriviruses reveals that the ectodomain of the major
glycoprotein is not the main determinant of equine arteritis virus
tropism in cell culture. Virology
288:283-294.[CrossRef][Medline]
- Faaberg,
K. S., and P. G. W. Plagemann.1995
. The envelope proteins of lactate
dehydrogenase-elevating virus and their membrane topography.Virology
212:512-525.[CrossRef][Medline]
- Godeny,
E. K., A. A. F. de Vries, X. C.
Wang, S. L. Smith, and R. J. de Groot.1998
. Identification of the leader-body junctions for the
viral subgenomic mRNAs and organization of the simian hemorrhagic fever
virus genome: evidence for gene duplication during arterivirus
evolution. J. Virol.
72:862-867.[Abstract/Free Full Text]
- Hedges,
J. F., U. B. R. Balasuriya, and
N. J. MacLachlan. 1999. The open reading
frame 3 of equine arteritis virus encodes an immunogenic glycosylated,
integral membrane protein. Virology
264:92-98.[CrossRef][Medline]
- Horzinek,
M. C., J. Maess, and R. Laufs. 1971. Studies
on the substructure of togaviruses. II. Analysis of equine arteritis,
rubella, bovine viral diarrhea, and hog cholera viruses. Arch.
Gesamte Virusforsch.
33:306-318.[CrossRef][Medline]
- Hyllseth,
B. 1973. Structural proteins of equine arteritis
virus. Arch. Gesamte Virusforsch.
40:177-188.[CrossRef][Medline]
- Kunkel,
T. A., K. Bebenek, and J. McClary. 1991.
Efficient site-directed mutagenesis using uracil-containing DNA.Methods Enzymol.
204:125-139.[Medline]
- Magnusson,
P., B. Hyllseth, and H. Marusyk. 1970. Morphological
studies on equine arteritis virus. Arch. Gesamte
Virusforsch.
30:105-112.[CrossRef][Medline]
- Mardassi,
H., P. Gonin, C. A. Gagnon, B. Massie, and S. Dea.1998
. A subset of porcine reproductive and respiratory
syndrome virus GP3 glycoprotein is released into the culture
medium of cells as a non-virion-associated and membrane-free (soluble)
form. J. Virol.
72:6298-6306.[Abstract/Free Full Text]
- Meulenberg,
J. J. M., and A. Petersen-den Besten.1996
. Identification and characterization of a sixth
structural protein of Lelystad virus: the glycoprotein GP2 encoded by
ORF2 is incorporated into virus particles. Virology
225:44-51.[CrossRef][Medline]
- Molenkamp,
R., H. van Tol, B. C. D. Rozier, Y. van der Meer,
W. J. M. Spaan, and E. J. Snijder.2000
. The arterivirus replicase is the only viral protein
required for genome replication and subgenomic mRNA transcription.J. Gen. Virol.
81:2491-2496.[Abstract/Free Full Text]
- Sambrook,
J., E. F. Fritsch, and T. Maniatis. 1989.
Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor
Laboratory Press, Cold Spring Harbor,
N.Y.
- Snijder,
E. J., H. van Tol, K. W. Pedersen, M.
J. B. Raamsman, and A. A. F. de
Vries. 1999. Identification of a novel structural
protein of arteriviruses. J. Virol.
73:6335-6345.[Abstract/Free Full Text]
- Snijder,
E. J., A. L. M. Wassenaar, and
W. J. M. Spaan. 1994. Proteolytic
processing of the replicase ORF1a protein of equine arteritis virus.J. Virol.
68:5755-5764.[Abstract/Free Full Text]
- van
Berlo, M. F., P. J. M. Rottier,
W. J. M. Spaan, and M. C. Horzinek.1986
. Equine arteritis virus-induced polypeptide
synthesis. J. Gen. Virol.
67:1543-1549.[Abstract/Free Full Text]
- van
Berlo, M. F., J. J. W. Zeegers,
M. C. Horzinek, and B. A. M. van der
Zeijst. 1983. Antigenic comparison of equine arteritis
virus (EAV) and lactic dehydrogenase virus (LDV); binding of
staphylococcal protein A to the nucleocapsid protein of EAV.Zentbl. Veterinarmed. B
30:297-304.
- van
Dinten, L. C., J. A. den Boon, A.
L. M. Wassenaar, W. J. M. Spaan, and
E. J. Snijder. 1997. An infectious
arterivirus cDNA clone: identification of a replicase point mutation
that abolishes discontinuous mRNA transcription. Proc. Natl.
Acad. Sci. USA
94:991-996.[Abstract/Free Full Text]
- van
Dinten, L. C., S. Rensen, W. J. M. Spaan,
A. E. Gorbalenya, and E. J. Snijder.1999
. Proteolytic processing of the open reading frame
1b-encoded part of arterivirus replicase is mediated by nsp4 serine
protease and is essential for virus replication. J.
Virol.
73:2027-2037.[Abstract/Free Full Text]
- van
Dinten, L. C., A. L. M. Wassenaar,
A. E. Gorbalenya, W. J. M. Spaan, and
E. J. Snijder. 1996. Processing of the
equine arteritis virus replicase ORF1b protein: identification of
cleavage products containing the putative viral polymerase and helicase
domains. J. Virol.
70:6625-6633.[Abstract/Free Full Text]
- Verheije,
M. H., T. J. M. Welting, H. T.
Jansen, P. J. M. Rottier, and J.
J. M. Meulenberg. 2002. Chimeric
arteriviruses generated by swapping of the M protein ectodomain rule
out a role of this domain in viral targeting. Virology
303:364-373.[CrossRef][Medline]
- Wassenaar,
A. L. M., W. J. M. Spaan,
A. E. Gorbalenya, and E. J. Snijder.1997
. Alternative proteolytic processing of the
arterivirus replicase ORF1a polyprotein: evidence that NSP2 acts as a
cofactor for the NSP4 serine protease. J.
Virol.
71:9313-9322.[Abstract]
- Wieringa,
R., A. A. F. de Vries, and P.
J. M. Rottier. 2003. Formation of
disulfide-linked complexes between the three minor envelope
glycoproteins (GP2b, GP3, and GP4) of
equine arteritis virus. J. Virol.
77:6216-6226.[Abstract/Free Full Text]
- Wieringa,
R., A. A. F. de Vries, M. J. B.
Raamsman, and P. J. M. Rottier.2002
. Characterization of two new structural
glycoproteins, GP3 and GP4, of equine arteritis
virus. J. Virol.
76:10829-10840.[Abstract/Free Full Text]
- Zeegers,
J. J. W., B. A. M. van der
Zeijst, and M. C. Horzinek. 1976. The
structural proteins of equine arteritis virus. Virology
73:200-205.[CrossRef][Medline]
Journal of Virology, December 2003, p. 12996-13004, Vol. 77, No. 24
0022-538X/03/$08.00+0 DOI: 10.1128/JVI.77.24.12996-13004.2003
Copyright © 2003, American
Society for
Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Lu, Z., Branscum, A. J., Shuck, K. M., Zhang, J., Dubovi, E. J., Timoney, P. J., Balasuriya, U. B.R.
(2008). Comparison of two real-time reverse transcription polymerase chain reaction assays for the detection of Equine arteritis virus nucleic acid in equine semen and tissue culture fluid. jvdi
20: 147-155
[Abstract]
[Full Text]
-
Costers, S., Delputte, P. L., Nauwynck, H. J.
(2006). Porcine reproductive and respiratory syndrome virus-infected alveolar macrophages contain no detectable levels of viral proteins in their plasma membrane and are protected against antibody-dependent, complement-mediated cell lysis.. J. Gen. Virol.
87: 2341-2351
[Abstract]
[Full Text]
-
Lee, C., Yoo, D.
(2005). Cysteine residues of the porcine reproductive and respiratory syndrome virus small envelope protein are non-essential for virus infectivity. J. Gen. Virol.
86: 3091-3096
[Abstract]
[Full Text]
-
Wissink, E. H. J., Kroese, M. V., van Wijk, H. A. R., Rijsewijk, F. A. M., Meulenberg, J. J. M., Rottier, P. J. M.
(2005). Envelope Protein Requirements for the Assembly of Infectious Virions of Porcine Reproductive and Respiratory Syndrome Virus. J. Virol.
79: 12495-12506
[Abstract]
[Full Text]
-
Zevenhoven-Dobbe, J. C., Greve, S., van Tol, H., Spaan, W. J. M., Snijder, E. J.
(2004). Rescue of disabled infectious single-cycle (DISC) Equine arteritis virus by using complementing cell lines that express minor structural glycoproteins. J. Gen. Virol.
85: 3709-3714
[Abstract]
[Full Text]
-
Wieringa, R., de Vries, A. A. F., van der Meulen, J., Godeke, G.-J., Onderwater, J. J. M., van Tol, H., Koerten, H. K., Mommaas, A. M., Snijder, E. J., Rottier, P. J. M.
(2004). Structural Protein Requirements in Equine Arteritis Virus Assembly. J. Virol.
78: 13019-13027
[Abstract]
[Full Text]
-
Pokidysheva, E., Milbradt, A. G., Meier, S., Renner, C., Haussinger, D., Bachinger, H. P., Moroder, L., Grzesiek, S., Holstein, T. W., Ozbek, S., Engel, J.
(2004). The Structure of the Cys-rich Terminal Domain of Hydra Minicollagen, Which Is Involved in Disulfide Networks of the Nematocyst Wall. J. Biol. Chem.
279: 30395-30401
[Abstract]
[Full Text]